samedan logo
 
 
spacer
home > pmps > winter 2021 > how rapid testing will play a huge role in our post- pandemic lives
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

How Rapid Testing Will Play a Huge Role in Our Post- Pandemic Lives

COVID-19 continues to restrict our lives, but with a number of vaccines now being rolled out across the world, there is light at the end of the tunnel. As we emerge from the worst of the pandemic, what’s clear is that in a post-pandemic environment, our demand for diagnostic tests will have changed – and so will our methods of meeting that demand.

A key reason for this change in attitude is realising the importance of testing. Whereas in the lead up to COVID-19, our approach to medical diagnostics was largely reactive, innovation in mass testing that has allowed us to tackle the pandemic is enabling a shift to a more pre-emptive approach to diagnostics. This not only helps prepare us for the next pandemic, but will help us identify and more effectively treat a variety of other conditions, too. Identifying diseases and medical conditions in their early stages will lead to better health outcomes for patients as well as vital money saved for the NHS.

The Logistical Breakthrough

The shift towards pre-emptive diagnostics is being enabled through innovations in laboratory diagnostics workflows, which uses proprietary software and robotics to run a mass scale COVID-19 diagnostics platform. Aside from the initial first stage, where samples collected need to be unpacked and prepped, the entire process is automated, which dramatically lowers the labour required, improves productivity, and minimises human error.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Miles Priestman, began as a scientist studying Biochemistry at the University of Oxford, UK, a Master’s in Systems and Synthetic Biology, and a PhD in Microbiology at Imperial College London. Before founding Salient Bio, an early stage biotech business operating in the molecular diagnostics space, Miles was a researcher at the London Biofoundry, focusing on the development of high-throughput workflows, including the automation of live cell systems.
spacer
Miles Priestman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envirotainer and Swiss WorldCargo complete the first commercial shipment using the new Releye® RAP

Stockholm, March 11, 2022: Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that the first commercial shipment using the new Releye® RAP container has been completed. The consignment was handled by Swiss WorldCargo, one of the leading carriers of intensive care pharmaceuticals.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement